APA (7th ed.) Citation

Goje, I., Goje, G., Ordodi, V. L., Ciobotaru, V. G., Ivan, V. S., Buzaș, R., . . . Lighezan, D. (2025). Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology. Pharmaceuticals (14248247), 18(5), 681. https://doi.org/10.3390/ph18050681

Chicago Style (17th ed.) Citation

Goje, Iacob-Daniel, Greta-Ionela Goje, Valentin Laurențiu Ordodi, Valentina Gabriela Ciobotaru, Vlad Sabin Ivan, Roxana Buzaș, Oana Tunea, Florina Bojin, and Daniel-Florin Lighezan. "Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology." Pharmaceuticals (14248247) 18, no. 5 (2025): 681. https://doi.org/10.3390/ph18050681.

MLA (9th ed.) Citation

Goje, Iacob-Daniel, et al. "Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology." Pharmaceuticals (14248247), vol. 18, no. 5, 2025, p. 681, https://doi.org/10.3390/ph18050681.